Efficacy of Prolonged-Release Melatonin 2 mg (PRM 2 mg) Prescribed for Insomnia in Hospitalized Patients for COVID-19: A Retrospective Observational Study
Carolina Bologna, Pasquale Madonna, Eduardo Pone
Journal of Clinical Medicine, doi:10.3390/jcm10245857
Background: we have observed the effect of insomnia treatment in clinical and prognostic differences of patients admitted for COVID-19 pneumonia in respiratory sub-intensive units that were administered a prolonged-release melatonin 2 mg (PRM 2 mg) therapy versus a group of patients out of therapy. Materials and Methods: We evaluated 40 patients on prolonged-release melatonin 2 mg (PRM 2 mg) therapy versus a control group of 40 patients out of therapy. Results: patients in the PRM 2 mg group had a shorter duration of therapy with non-invasive ventilation (5.2 ± 3.0 vs. 12.5 ± 4.2; p < 0.001), with a shorter stay in sub-intensive care (12.3 ± 3.2 vs. 20.1 ± 6.1; p < 0.001), and, therefore, a shorter overall duration of hospitalization (31.3 ± 6.8 vs. 34.3 ± 6.9 p = 0.03). In addition, a lower incidence of delirium was found (2.2 ± 1.1 vs. 3.3 ± 1.3; p < 0.001). Conclusions: A significant increase in sleep hours and a reduction in delirium episodes occurs in hospitalized insomniac patients treated with PRM 2 mg, compared to untreated patients. Based on these preliminary results, we can assume that there are benefits of prolonged-release melatonin 2 mg in COVID-19 therapy.
Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.
Conflicts of Interest: The authors declare no conflict of interest.
References
Anderson, Reiter, Melatonin: Roles in influenza, COVID-19, and other viral infections, R. J. Rev. Med. Virol
Arbon, Knurowska, Dijk, Randomised clinical trial of the effects of prolonged-release melatonin, temazepam and zolpidem on slow-wave activity during sleep in healthy people, J. Psychopharmacol,
doi:10.1177/0269881115581963Bahrampour, Juybari, Pourhanifeh, Hosseinzadeh, Hemati et al., Melatonin potentials against viral infections including COVID-19: Current evidence and new findings, Virus Res,
doi:10.1016/j.virusres.2020.198108Baller, Hogan, Fusunyan, Ivkovic, Luccarelli et al., Neurocovid: Pharmacological Recommendations for Delirium Associated With COVID-19, Psychosomatics,
doi:10.1016/j.psym.2020.05.013Cardinali, Brown, Pandi-Perumal, Can Melatonin Be a Potential "Silver Bullet" in Treating COVID-19 Patients, Diseases,
doi:10.3390/diseases8040044Cerezo, Leal, Álvarez-Fernández, Hornedo-Ortega, Troncoso et al., Quality control and determination of melatonin in food supplements, J. Food Compos. Anal,
doi:10.1016/j.jfca.2015.09.013Duggan, Van, Ely, Assessment in Critically Ill Older Adults: Considerations During the COVID-19 Pandemic, Crit. Care Clin,
doi:10.1016/j.ccc.2020.08.009Erland, Saxena, Melatonin Natural Health Products and Supplements: Presence of Serotonin and Significant Variability of Melatonin Content, J. Clin. Sleep Med,
doi:10.5664/jcsm.6462Lemoine, Laudon, Nir, Zisapel, Prolonged-release melatonin for insomnia-An open-label long-term study of efficacy, safety, and withdrawal, Ther. Clin. Risk Manag,
doi:10.2147/TCRM.S23036Luthringer, Muzet, Zisapel, Staner, The effect of prolonged-release melatonin on sleep measures and psychomotor performance in elderly patients with insomnia, Int. Clin. Psychopharmacol,
doi:10.1097/YIC.0b013e32832e9b08Martín Giménez, Inserra, Tajer, Mariani, Ferder et al., Lungs as target of COVID-19 infection: Protective common molecular mechanisms of vitamin D and melatonin as a new potential synergistic treatment, Life Sci,
doi:10.1016/j.lfs.2020.117808Missiry, El-Missiry, Othman, Melatonin is a potential adjuvant to improve clinical outcomes in individuals with obesity and diabetes with coexistence of COVID-19, J. Pharmacol,
doi:10.1016/j.ejphar.2020.173329Otmani, Demazieres, Staner, Jacob, Nir et al., Effects of prolonged-release melatonin, zolpidem, and their combination on psychomotor functions, memory recall, and driving skills in healthy middle aged and elderly volunteers, Hum. Psychopharmacol. Clin. Exp,
doi:10.1002/hup.980Otmani, Metzger, Guichard, Danjou, Nir et al., Effects of prolonged-release melatonin and zolpidem on postural stability in older adults, Hum. Psychopharmacol. Clin. Exp,
doi:10.1002/hup.2219Palagini, Manni, Aguglia, Amore, Brugnoli et al., Expert Opinions and Consensus Recommendations for the Evaluation and Management of Insomnia in Clinical Practice: Joint Statements of Five Italian Scientific Societies, Front. Psychiatry,
doi:10.3389/fpsyt.2020.00558Pinto, Ferri, Pengo, Lombardi, Pucci et al., The Italian Society of Hypertension. Diagnostic and Therapeutic Approach to Sleep Disorders, High Blood Pressure and Cardiovascular Diseases: A Consensus Document by the Italian Society of Hypertension (SIIA), High Blood Press Cardiovasc. Prev,
doi:10.1007/s40292-021-00436-yReiter, Abreu-Gonzalez, Marik, Dominguez-Rodriguez, Therapeutic Algorithm for Use of Melatonin in Patients With COVID-19, Front. Med,
doi:10.3389/fmed.2020.00226Wade, Ford, Crawford, Mcmahon, Nir et al., Efficacy of prolonged release melatonin in insomnia patients aged 55-80 years: Quality of sleep and next-day alertness outcomes, Curr. Med. Res. Opin,
doi:10.1185/030079907X233098Wilson, Anderson, British Association for Psycopharmacology consensus statement on evidence based treatment of insomnia, parasomnias and citrcadian rhythm disorders: An update, J. Psychopharmacol,
doi:10.1177/0269881119855343Zisapel, New perspectives on the role of melatonin in human sleep, circadian rhythms and their regulation, Br. J. Pharmacol,
doi:10.1111/bph.14116Öztürk, Akbulut, Güney, Turk Melatonin, aging, and COVID-19: Could melatonin be beneficial for COVID-19 treatment in the elderly?, Med. Sci,
doi:10.3906/sag-2005-356DOI record:
{
"DOI": "10.3390/jcm10245857",
"ISSN": [
"2077-0383"
],
"URL": "http://dx.doi.org/10.3390/jcm10245857",
"abstract": "<jats:p>Background: we have observed the effect of insomnia treatment in clinical and prognostic differences of patients admitted for COVID-19 pneumonia in respiratory sub-intensive units that were administered a prolonged-release melatonin 2 mg (PRM 2 mg) therapy versus a group of patients out of therapy. Materials and Methods: We evaluated 40 patients on prolonged-release melatonin 2 mg (PRM 2 mg) therapy versus a control group of 40 patients out of therapy. Results: patients in the PRM 2 mg group had a shorter duration of therapy with non-invasive ventilation (5.2 ± 3.0 vs. 12.5 ± 4.2; p < 0.001), with a shorter stay in sub-intensive care (12.3 ± 3.2 vs. 20.1 ± 6.1; p < 0.001), and, therefore, a shorter overall duration of hospitalization (31.3 ± 6.8 vs. 34.3 ± 6.9 p = 0.03). In addition, a lower incidence of delirium was found (2.2 ± 1.1 vs. 3.3 ± 1.3; p < 0.001). Conclusions: A significant increase in sleep hours and a reduction in delirium episodes occurs in hospitalized insomniac patients treated with PRM 2 mg, compared to untreated patients. Based on these preliminary results, we can assume that there are benefits of prolonged-release melatonin 2 mg in COVID-19 therapy.</jats:p>",
"alternative-id": [
"jcm10245857"
],
"author": [
{
"ORCID": "http://orcid.org/0000-0002-2007-3835",
"affiliation": [],
"authenticated-orcid": false,
"family": "Bologna",
"given": "Carolina",
"sequence": "first"
},
{
"affiliation": [],
"family": "Madonna",
"given": "Pasquale",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Pone",
"given": "Eduardo",
"sequence": "additional"
}
],
"container-title": [
"Journal of Clinical Medicine"
],
"content-domain": {
"crossmark-restriction": false,
"domain": []
},
"created": {
"date-parts": [
[
2021,
12,
14
]
],
"date-time": "2021-12-14T16:11:35Z",
"timestamp": 1639498295000
},
"deposited": {
"date-parts": [
[
2021,
12,
15
]
],
"date-time": "2021-12-15T03:16:05Z",
"timestamp": 1639538165000
},
"indexed": {
"date-parts": [
[
2021,
12,
16
]
],
"date-time": "2021-12-16T06:47:30Z",
"timestamp": 1639637250710
},
"is-referenced-by-count": 0,
"issn-type": [
{
"type": "electronic",
"value": "2077-0383"
}
],
"issue": "24",
"issued": {
"date-parts": [
[
2021,
12,
14
]
]
},
"journal-issue": {
"issue": "24",
"published-online": {
"date-parts": [
[
2021,
12
]
]
}
},
"language": "en",
"license": [
{
"URL": "https://creativecommons.org/licenses/by/4.0/",
"content-version": "vor",
"delay-in-days": 0,
"start": {
"date-parts": [
[
2021,
12,
14
]
],
"date-time": "2021-12-14T00:00:00Z",
"timestamp": 1639440000000
}
}
],
"link": [
{
"URL": "https://www.mdpi.com/2077-0383/10/24/5857/pdf",
"content-type": "unspecified",
"content-version": "vor",
"intended-application": "similarity-checking"
}
],
"member": "1968",
"original-title": [],
"page": "5857",
"prefix": "10.3390",
"published": {
"date-parts": [
[
2021,
12,
14
]
]
},
"published-online": {
"date-parts": [
[
2021,
12,
14
]
]
},
"publisher": "MDPI AG",
"reference": [
{
"DOI": "10.1016/j.lfs.2020.117583",
"doi-asserted-by": "publisher",
"key": "ref1"
},
{
"DOI": "10.1002/rmv.2109",
"doi-asserted-by": "publisher",
"key": "ref2"
},
{
"DOI": "10.1080/08830185.2020.1756284",
"doi-asserted-by": "publisher",
"key": "ref3"
},
{
"DOI": "10.3390/diseases8040044",
"doi-asserted-by": "publisher",
"key": "ref4"
},
{
"DOI": "10.5664/jcsm.7172",
"doi-asserted-by": "publisher",
"key": "ref5"
},
{
"DOI": "10.1016/j.jfca.2015.09.013",
"doi-asserted-by": "publisher",
"key": "ref6"
},
{
"DOI": "10.5664/jcsm.6462",
"doi-asserted-by": "publisher",
"key": "ref7"
},
{
"DOI": "10.3389/fpsyt.2020.00558",
"doi-asserted-by": "publisher",
"key": "ref8"
},
{
"DOI": "10.1111/bph.14116",
"doi-asserted-by": "publisher",
"key": "ref9"
},
{
"DOI": "10.1185/030079907X233098",
"doi-asserted-by": "publisher",
"key": "ref10"
},
{
"DOI": "10.1097/YIC.0b013e32832e9b08",
"doi-asserted-by": "publisher",
"key": "ref11"
},
{
"DOI": "10.2147/TCRM.S23036",
"doi-asserted-by": "publisher",
"key": "ref12"
},
{
"DOI": "10.1177/0269881115581963",
"doi-asserted-by": "publisher",
"key": "ref13"
},
{
"DOI": "10.1002/hup.980",
"doi-asserted-by": "publisher",
"key": "ref14"
},
{
"DOI": "10.1002/hup.2219",
"doi-asserted-by": "publisher",
"key": "ref15"
},
{
"DOI": "10.1177/0269881119855343",
"doi-asserted-by": "publisher",
"key": "ref16"
},
{
"DOI": "10.1007/s40292-021-00436-y",
"doi-asserted-by": "publisher",
"key": "ref17"
},
{
"DOI": "10.1016/j.psym.2020.05.013",
"doi-asserted-by": "publisher",
"key": "ref18"
},
{
"DOI": "10.1016/j.ccc.2020.08.009",
"doi-asserted-by": "publisher",
"key": "ref19"
},
{
"DOI": "10.1016/j.lfs.2020.117808",
"doi-asserted-by": "publisher",
"key": "ref20"
},
{
"DOI": "10.1016/j.virusres.2020.198108",
"doi-asserted-by": "publisher",
"key": "ref21"
},
{
"DOI": "10.1016/j.sleep.2020.05.028",
"doi-asserted-by": "publisher",
"key": "ref22"
},
{
"DOI": "10.1016/j.ejphar.2020.173329",
"doi-asserted-by": "publisher",
"key": "ref23"
},
{
"DOI": "10.3389/fmed.2020.00226",
"doi-asserted-by": "publisher",
"key": "ref24"
},
{
"DOI": "10.3906/sag-2005-356",
"doi-asserted-by": "publisher",
"key": "ref25"
}
],
"reference-count": 25,
"references-count": 25,
"relation": {},
"score": 1,
"short-container-title": [
"JCM"
],
"short-title": [],
"source": "Crossref",
"subject": [
"General Medicine"
],
"subtitle": [],
"title": [
"Efficacy of Prolonged-Release Melatonin 2 mg (PRM 2 mg) Prescribed for Insomnia in Hospitalized Patients for COVID-19: A Retrospective Observational Study"
],
"type": "journal-article",
"volume": "10"
}
